Kiniksa Pharmaceuticals International, plc (KNSA)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1730430 · fiscal year ends in Dec
Closing price $97.63 on 29 Oct 2026; 52-week range $37.01 to $97.63.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $946.0M
- Revenue growth
- 58.2%
- Net income, last twelve months
- $109.6M
- Earnings per share
- $1.30
- Gross margin
- 90.2%
- Operating margin
- 13.8%
- Net margin
- 11.6%
- Free cash flow
- $197.2M
- Return on equity
- 15.4%
- Market value
- $8.3B
- Price to earnings
- 75.1x
- Cash
- $81.7M
- Debt
- $0
- Debt to equity
- 0.00
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $677.6M | $77.2M | $59.0M | $0.75 | $136.4M | 10-K filed 24 Feb 2026 |
| FY2024 | 31 Dec 2024 | $423.2M | -$45.6M | -$43.2M | -$0.60 | $25.4M | 10-K filed 25 Feb 2025 |
| FY2023 | 31 Dec 2023 | $270.3M | -$25.2M | $14.1M | $0.20 | $13.2M | 10-K filed 25 Feb 2025 |
| FY2022 | 31 Dec 2022 | $220.2M | $9.8M | $183.4M | $2.60 | $5.7M | 10-K filed 25 Feb 2025 |
| FY2021 | 31 Dec 2021 | $38.5M | -$156.6M | -$157.9M | -$2.30 | -$126.7M | 10-K filed 24 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $286.0M | $47.3M | $0.56 |
| Q2 FY2026 | 30 Jun 2026 | $243.6M | $25.4M | $0.30 |
| Q1 FY2026 | 31 Mar 2026 | $214.3M | $22.6M | $0.27 |
| Q4 FY2025 | 31 Dec 2025 | $202.1M | $14.2M | $0.17 |
| Q3 FY2025 | 30 Sep 2025 | $180.9M | $18.4M | $0.23 |
| Q2 FY2025 | 30 Jun 2025 | $156.8M | $17.8M | $0.23 |
| Q1 FY2025 | 31 Mar 2025 | $137.8M | $8.5M | $0.11 |
| Q4 FY2024 | 31 Dec 2024 | $122.5M | -$8.9M | -$0.12 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2024
| Segment | Revenue | Share |
|---|---|---|
| Product revenue, net | $417.0M | 98.5% |
| License and collaboration revenue | $6.2M | 1.5% |
Company events
The newest 8-K filings of 85 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Oct 2026 | 8-K | Leadership change | 5.02 |
| 28 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 29 May 2026 | 8-K | Shareholder vote | 5.07 |
| 26 May 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 1 May 2026 | 8-K | Leadership change | 5.02 |
| 28 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 14 Jan 2026 | 8-K | Leadership change | 5.02 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 3 Sep 2025 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 226 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 10-Q | 30 Sep 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 22 Oct 2026 | 8-K | 17 Oct 2026 |
| 28 Jul 2026 | 10-Q | 30 Jun 2026 |
| 28 Jul 2026 | 8-K | 28 Jul 2026 |
| 29 May 2026 | 8-K | 29 May 2026 |
| 26 May 2026 | 8-K | 21 May 2026 |
| 1 May 2026 | 8-K | 30 Apr 2026 |
| 28 Apr 2026 | 10-Q | 31 Mar 2026 |
| 28 Apr 2026 | 8-K | 28 Apr 2026 |
| 16 Apr 2026 | ARS | 31 Dec 2025 |
| 16 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 3 Sep 2026 | Megna Michael R, CHIEF ACCOUNTING OFFICER | Sale under a trading plan | 4,600 | $80.30 | $369.4K | 29,062 | 3 Sep 2026 |
| 29 Jul 2026 | Cole G Bradley, Director | Sale outside a trading plan | 3,673 | $81.43 | $299.1K | 11,672 | 31 Jul 2026 |
| 1 May 2026 | Paolini John F., CHIEF MEDICAL OFFICER | Sale under a trading plan | 37,327 | $53.52 | $2.0M | 86,720 | 5 May 2026 |
| 1 May 2026 | Paolini John F., CHIEF MEDICAL OFFICER | Sale under a trading plan | 21,097 | $54.04 | $1.1M | 65,623 | 5 May 2026 |
| 1 May 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 48,565 | $54.02 | $2.6M | 0 | 1 May 2026 |
| 30 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 2,141 | $54.01 | $115.6K | 0 | 30 Apr 2026 |
| 29 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 22,544 | $54.01 | $1.2M | 0 | 30 Apr 2026 |
| 28 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 74,635 | $50.43 | $3.8M | 409,019 | 30 Apr 2026 |
| 28 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 113,673 | $51.47 | $5.9M | 295,346 | 30 Apr 2026 |
| 28 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 243,596 | $52.02 | $12.7M | 51,750 | 30 Apr 2026 |
| 28 Apr 2026 | Patel Sanj K, CHAIRMAN & CEO | Sale under a trading plan | 51,750 | $54.02 | $2.8M | 0 | 30 Apr 2026 |
| 28 Apr 2026 | Quart Barry D, Director | Sale under a trading plan | 13,099 | $50.10 | $656.3K | 12,546 | 29 Apr 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 3 Sep 2026 | Megna Michael R, Officer | 4,600 | $369.4K | 3 Sep 2026 |
| 29 Jul 2026 | Cole G Bradley, Director | 3,673 | $299.1K | 29 Jul 2026 |
| 29 Jul 2026 | Tessari Eben, Former Affiliate | 67,062 | $5.3M | 29 Jul 2026 |
| 1 May 2026 | Paolini John F., Officer | 58,424 | $3.1M | 1 May 2026 |
| 28 Apr 2026 | Patel Sanj K, Officer, Director | 344,591 | $17.8M | 28 Apr 2026 |
| 9 Apr 2026 | Moat Ross, Officer | 1,703 | $79.5K | 9 Apr 2026 |
| 9 Apr 2026 | Megna Michael R, Officer | 6,625 | $309.3K | 9 Apr 2026 |
| 6 Apr 2026 | Moat Ross, Officer | 2,367 | $115.0K | 6 Apr 2026 |
| 6 Apr 2026 | Quart Barry D, Director | 20,000 | $1.0M | 6 Apr 2026 |
| 6 Apr 2026 | Patel Sanj K, Officer, Director | 219,591 | $11.0M | 6 Apr 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G | 5.5% | 2.5M |
| 26 May 2026 | Baker Bros. Advisors LP | 13D amended | 7% | 3.3M |
| 6 May 2026 | FMR LLC | 13G amended | 14.8% | 6.8M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 6 Mar 2026 | FMR LLC | 13G | 10.6% | 4.9M |
| 13 Feb 2026 | Rubric Capital Management LP | 13G amended | 7.37% | 3.3M |
| 31 Oct 2025 | The Vanguard Group | 13G amended | 7.04% | 3.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.8M | -0.4% | 6.78 |
| 30 Sep 2026 | 3.8M | -2.53% | 6.41 |
| 15 Sep 2026 | 3.9M | +2.32% | 7.21 |
| 31 Aug 2026 | 3.8M | -11.55% | 8.69 |
| 14 Aug 2026 | 4.3M | -0.77% | 9.56 |
| 31 Jul 2026 | 4.3M | -4.29% | 4.99 |
| 15 Jul 2026 | 4.5M | +8.55% | 6.85 |
| 30 Jun 2026 | 4.2M | +41% | 2.88 |
Funds that hold it
From each fund's latest Form 13F.
292 funds held it at 30 Jun 2026: 149 added and 81 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 6,971,361 | $445.8M | +147,661 |
| Rubric Capital Management LP | 3,999,800 | $255.8M | +249,800 |
| Baker Bros. Advisors LP | 2,834,643 | $181.3M | +8,397 |
| BlackRock, Inc. | 2,739,615 | $175.2M | +2,252,878 |
| Tang Capital Management LLC | 2,259,889 | $144.5M | 0 |
| Vanguard Portfolio Management LLC | 1,911,335 | $122.2M | +145,067 |
| Vanguard Capital Management LLC | 1,360,840 | $87.0M | +27,747 |
| Morgan Stanley | 1,011,143 | $64.7M | +13,357 |
| Arrowstreet Capital, Limited Partnership | 957,514 | $61.2M | +64,848 |
| Spruce Street Capital LP | 918,070 | $58.7M | +157,007 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B